Anders L. Carlson, MD
Senior Research Investigator
About

Affiliations/other offices held:聽Medical director, International Diabetes Center, and director, 开云体育 diabetes program; assistant professor, University of Minnesota Medical School.

Joined the Institute:听2015

Education and training:聽MD, University of Minnesota Medical School; fellowship in endocrinology, diabetes and metabolism, University of Vermont; residency in internal medicine, Hennepin County Medical Center, Minneapolis.

Overview/research interests:聽Dr. Carlson鈥檚 research interests include diabetes technology, diabetes care delivery and hyperglycemia in oncology patients. Dr. Carlson has participated in several clinical trials through International Diabetes Center focusing on diabetes technology and new therapeutics. He also has experience using molecular techniques in beta cell research.

CV
Affiliation
positions
  • Sr. Research Investigator, Diabetes
  • Medical Director, International Diabetes Center, International Diabetes Center 2015 -
    • Publications While At 开云体育
    selected publications
    Journal Article
  • Automated insulin delivery in adults with type 2 diabetes: a nonrandomized clinical trial. 
    JAMA network open. 2025
  • Continuous glucose monitoring-measured glucose levels during oral glucose tolerance testing in pregnancy. 
    Diabetes Technology & Therapeutics. 2025
  • Differential treatment effects on beta-cell function using model-based parameters in type 2 diabetes: results from the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). 
    Diabetes care. 2025
  • Glycaemic outcomes in adults with type 2 diabetes over 34鈥墂eeks with the Omnipod庐 5 Automated Insulin Delivery System. 
    Diabetes, Obesity & Metabolism. 2025
  • Safety and effectiveness of MiniMed鈩� 780G advanced hybrid closed-loop insulin intensification in adults with insulin-requiring type 2 diabetes. 
    Diabetes Technology & Therapeutics. 2025
  • -cell function over time on glycemic outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): differential treatment effects of dual therapy. 
    Diabetes care. 2024
  • Continuous glucose monitoring prediction of gestational diabetes mellitus and perinatal complications. 
    Diabetes Technology & Therapeutics. 2024
  • Continuous glucose monitoring profiles in pregnancies with and without gestational diabetes mellitus. 
    Diabetes care. 2024
  • Continuous glucose monitoring-derived differences in pregnancies with and without adverse perinatal outcomes. 
    Obstetrics and Gynecology. 2024
  • Control-IQ technology use in individuals with high insulin requirements: results from the Multicenter Higher-IQ Trial. 
    Journal of Diabetes Science and Technology. 2024
  • Expert panel recommendations for a standardized ambulatory glucose profile report for connected insulin pens. 
    Diabetes Technology & Therapeutics. 2024
  • Glucose levels measured with continuous glucose monitoring in uncomplicated pregnancies. 
    BMJ open diabetes research & care. 2024
  • Increase access, reduce disparities: recommendations for modifying medicaid CGM coverage eligibility criteria. 
    Journal of Diabetes Science and Technology. 2024
  • The use of rescue insulin in the glycemia reduction approaches in diabetes: a comparative effectiveness聽study聽(GRADE). 
    Diabetes care. 2024
  • Two years with a tubeless automated insulin delivery system: a single-arm multicenter trial in children, adolescents, and adults with Type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2024
  • BMI, insulin sensitivity, and cognition in early type 2 diabetes: The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study. 
    Obesity (Silver Spring, Md.). 2023
  • Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. 
    Endocrine Reviews. 2023
  • Improved glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: results from a randomized controlled trial. 
    Diabetes Technology & Therapeutics. 2023
  • Safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes: from injections to hybrid closed-loop therapy. 
    Diabetes care. 2023
  • Safety and glycemic outcomes during the MiniMed(TM) advanced hybrid closed-loop system pivotal trial in children and adolescents with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2023
  • Benefit of continuous glucose monitoring in reducing hypoglycemia is sustained through 12 months of use among older adults with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2022
  • Can faster aspart be used to optimize glycemic control with insulin pump therapy? From expectations to lessons learned after a year of use in the United States. 
    Clinical Diabetes. 2022
  • How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: findings from the first investigation with the Omnipod庐 5 System. 
    Diabetes Research and Clinical Practice. 2022
  • Real-world evidence supporting Tandem Control-IQ Hybrid Closed-Loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations. 
    Diabetes Technology & Therapeutics. 2022
  • Safety and glycemic outcomes during the MiniMed鈩� Advanced Hybrid Closed-Loop System Pivotal Trial in adolescents and adults with type 1 diabetes. 
    Diabetes Technology & Therapeutics. 2022
  • Symptomatic diabetic autonomic neuropathy in type 1 diabetes (T1D): findings from the T1D exchange. 
    Journal of Diabetes and Its Complications. 2022
  • A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. 
    Lancet (London, England). 2021
  • Continuous glucose monitoring integration for remote diabetes management: virtual diabetes care with case studies. 
    Diabetes Technology & Therapeutics. 2021
  • Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. 
    JAMA. 2021
  • Hypoglycemia and glycemic control in older adults with type 1 diabetes: baseline results from the WISDM Study. 
    Journal of Diabetes Science and Technology. 2021
  • Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system. 
    Diabetes Research and Clinical Practice. 2021
  • Initiating insulin in the emergency center and urgent care to prevent hospital admission for patients with hyperglycemia: a unique insulin starter kit. 
    Journal of Diabetes Science and Technology. 2021
  • Lost in translation: a disconnect between the science and Medicare coverage criteria for continuous subcutaneous insulin infusion. 
    Diabetes Technology & Therapeutics. 2021
  • Making sense of glucose metrics in diabetes: linkage between postprandial glucose (PPG), time in range (TIR) & hemoglobin A1c (A1C). 
    Postgraduate Medicine. 2021
  • Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. 
    Diabetes care. 2021
  • Renal complications and duration of diabetes: an international comparison in persons with type 1 diabetes. 
    Diabetes Therapy. 2021
  • The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin. 
    Diabetes care. 2021
  • Trial of a new diabetes education model: closing the gap in health disparity for people with diabetes. 
    Journal of Diabetes Science and Technology. 2021
  • Ultrarapid lispro demonstrates similar time in target range to lispro with a hybrid closed-loop system. 
    Diabetes Technology & Therapeutics. 2021
  • Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial. 
    JAMA. 2020
  • International Diabetes Center: COVID-19 won't stop us from fulfilling our mission. 
    Journal of Diabetes Science and Technology. 2020
  • Evaluation of insulin glargine and exenatide alone and in combination: a randomized clinical trial with continuous glucose monitoring and ambulatory glucose profile analysis. 
    Endocrine Practice. 2019
  • Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy. 
    Journal of Diabetes and Its Complications. 2019
  • The relationships between time in range, hyperglycemia metrics, and HbA1c. 
    Journal of Diabetes Science and Technology. 2019
  • Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial. 
    Diabetes, Obesity & Metabolism. 2018
  • The hybrid closed loop therapy system: a step closer to an artificial pancreas. 
    Minn Physician. 2017
  • Bilateral adrenal incidentalomas: a case report and review of diagnostic challenges. 
    Case reports in endocrinology. 2013
    • Editorial Article
  • Duration of hybrid closed-loop insulin therapy to achieve representative glycemic outcomes in adults with type 1 diabetes [editorial]. 
    Diabetes care.  43. 2020
    • Conference Paper
  • Diabetes technology in 2019 [invited speaker]
    2019
  • Diabetes technology in clinical practice [invited speaker]
    2018
  • The connection between dementia and diabetes [invited speaker]
    2017
  • Diabetes technology: beyond insulin pumps [invited speaker]
    2016
    • Conference Poster
  • Autonomic neuropathy in type 1 diabetes (T1D): findings from the T1D Exchange [poster]
    2019
  • Hybrid closed-loop in adults with type 1 diabetes: impact of baseline A1c on glucose outcomes and insulin delivery [poster]
    2019
  • Optimal sampling duration of hybrid closed-loop therapy to determine long-term glycemic control in adults with type 1 diabetes [poster]
    2019
  • Efficacy and safety of faster aspart compared with insulin aspart both with insulin degludec in adults with T1D [poster]
    2018
  • Hypoglycaemia with mealtime fast-acting insulin aspart versis insulin aspart across two large type 1 diabetes trials [poster]
    2018
  • Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy [poster]
    2018
  • Improved glycemic control with carbohydrate counting for adjustment of fast-acting insulin aspart versus insulin aspart in subjects with type 1 diabetes [poster]
    2018
  • Incidence of diabetes and hyperglycemia among patients receiving glucocorticoids with chemotherapy [poster]
    2018
  • Increased HbA1c variability may shorten time to microalbuminuria development in type 1 diabetes (T1D) [poster]
    2018
    • Review
  • Primary care and diabetes technologies and treatments [review]. 
    Diabetes Technology & Therapeutics. 2025
  • Primary care and diabetes technologies and treatments [review]. 
    Diabetes Technology & Therapeutics. 2024
  • Primary care and diabetes technologies and treatments [review]. 
    Diabetes Technology & Therapeutics. 2023
  • Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis [meta-analysis]. 
    BMJ open diabetes research & care. 2022
  • Primary care and diabetes technologies and treatments [review]. 
    Diabetes Technology & Therapeutics. 2022
  • Primary care and diabetes technologies and treatments [review]. 
    Diabetes Technology & Therapeutics. 2021
  • What's wrong with this picture? A critical review of current Centers for Medicare & Medicaid Services coverage criteria for continuous glucose monitoring [review]. 
    Diabetes Technology & Therapeutics. 2021
  • HbA1c: the glucose management indicator, time in range, and standardization of continuous glucose monitoring reports in clinical practice [review]. 
    Endocrinology and Metabolism Clinics of North America. 2020
  • Advanced technology in the management of diabetes: which comes first-continuous glucose monitor or insulin pump [review]?. 
    Current Diabetes Reports. 2019
  • Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice [review]. 
    Diabetes Technology & Therapeutics. 2019
  • Clinical use of continuous glucose monitoring in adults with type 2 diabetes [review]. 
    Diabetes Technology & Therapeutics. 2017
    • Abstract
  • Patient-reported outcomes for 2,335 adults with type 2 diabetes using the omnipod insulin management system show glycemic improvement over first 90 days of use [abstract]. 
    Diabetes. 2020
  • Safety and glycemic outcomes of the MiniMed advanced hybrid closed-loop (AHCL) system in subjects with T1D [abstract]. 
    Diabetes. 2020
  • Ultra-Rapid Lispro (URLi) demonstrates similar time-in-target range to Humalog with the Medtronic MiniMed 670G Hybrid Closed-Loop System [abstract]. 
    Diabetes. 2020
    • Audio Document
  • CGM use in type 2 diabetes
    2018
    • Patent
  • Methods for treating patients with impaired awareness of hypoglycemia
    2021
  • Treatment of hypoglycemia unawareness with intranasal insulin
    2017
    • presentations
    Presentation
  • Beyond A1C--applying uniform metrics in the clinical use of continuous glucose monitoring [presentation], American Diabetes Association (ADA) 79th Scientific Sessions
  • Challenges in technology: difficult pump and CGM cases [presentation], Endocrine Society Clinical Endocrinology Update
  • Diabetes treatment in the elderly [presentation], Endocrine Society Clinical Endocrinology Update
  • Exposure to hypoglycemia in older adults with type 1 diabetes: baseline characteristics using continuous glucose monitoring data [presentation], Endocrine Society Annual Meeting
  • Glucose monitoring: advances, pitfalls and clinical relevance [presentation], American Diabetes Association (ADA) 78th Scientific Sessions
  • New insulin possibilities in diabetes care [presentation], Endocrine Society Dimensions in Diabetes
  • Outcomes of a telehealth initiative for diabetes management in primary care [presentation], American Diabetes Association (ADA) 77th Scientific Sessions
  • Prevention and management of severe hypoglycemia and hypoglycemia unawareness: incorporating sensor technology [presentation], Endocrine Society Clinical Endocrinology Update
  • Standardized report for pattern recognition: role of the Ambulatory Glucose Profile (AGP) in closed loop therapy [presentation], National Institutes of Health Fourth Artificial Pancreas Workshop: Testing and Adoption of Current and Emerging Technologies
  • The clinical use of continuous glucose monitoring metrics beyond A1c [presentation], Sidra Medicine Conference on Understanding Diabetes Obesity and Stroke
  • Time in range: the time is now [presentation], Endocrine Society Annual Meeting
  • What is new in continuous glucose monitoring [presentation]?, Endocrine Society Clinical Endocrinology Update
    • Invited Talk
  • Hybrid closed loop technology in clinical management of type 1 diabetes [keynote speaker], Sidra Medicine Conference on Understanding Diabetes Obesity and Stroke
    • Workshop
  • Shared decision making in diabetes care [workshop, invited speaker], International Diabetes Center Rising Stars Program
    • Contact
    full name
  • Anders L. Carlson, MD
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration
    More Info